Predicting Survival for Chimeric Antigen Receptor T-Cell Therapy: A Validation of Survival Models Using Follow-Up Data From ZUMA-1

•Cure-based models were able to produce consistent and accurate extrapolations of longer-term survival for patients treated with axicabtagene ciloleucel, even with limited follow-up data.•Models without a cure fraction may provide reasonable fits to the Kaplan-Meier estimate but did not seem to extrapolate well in our study, particularly standard parametric models.•Cure-based models provide a useful tool to allow for the estimation of plausible survival extrapolations based on limited follow-up data and inform timely and accurate decision making.